ArticleAnnals of hematology2026
Prognostic impact of monocyte percentage and extranodal involvement in classical hodgkin lymphoma: A multicenter real-world study of 547 chinese patients.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Classical Hodgkin lymphoma (cHL) has excellent survival outcomes, but real-world data from large-scale cohorts in China remain limited. This multicenter study characterized the clinical profile of a large Chinese cHL cohort to evaluate the efficacy of BV-containing regimens and investigate the prognostic value of clinical, nutritional, and biological markers, including peripheral monocyte percentage (M%). We retrospectively analyzed 547 patients with pathologically confirmed cHL from 10 centers between 2010 and 2023. Clinical characteristics and treatment outcomes were assessed. Propensity score matching (PSM) was employed to minimize selection bias when comparing progression-free survival (PFS) between treatment groups. Multivariate Cox regression models identified independent prognostic factors. The cohort featured a high prevalence of advanced-stage disease (55.0%) and the mixed cellularity subtype (34.4%), distinct from Western populations. While ABVD remained the dominant first-line regimen, the adoption of BV + AVD increased over time. In the PSM analysis, first-line BV + AVD demonstrated a numerically higher 3-year PFS compared with ABVD (95.2% vs. 88.9%), although this difference did not reach statistical significance (P = 0.359). Multivariate analysis identified decreased albumin and elevated M% as independent predictors of inferior PFS, while a focused biological model confirmed elevated M% and bone involvement as independent predictors of inferior overall survival. This study provides comprehensive real-world evidence delineating the clinical landscape of cHL in Chinese patients. While BV + AVD showed a favorable trend toward improved PFS, statistical superiority was not reached, warranting further investigation in larger cohorts. Furthermore, baseline nutritional status (albumin), tumor microenvironment surrogates (M%), and distinct extranodal infiltration (bone involvement) emerged as key prognostic markers, suggesting a need for risk-adapted strategies and potentially intensified therapies in high-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.